Amgen: Biotech Giant's Path to Growth and Recovery
Amgen has navigated headwinds to chart a path toward renewed growth. This analysis breaks down the catalysts, risks, ...
Budget implementation can fail when assumptions misalign with reality. This piece explains failure points and how to correct course.
16,076 articlesAmgen has navigated headwinds to chart a path toward renewed growth. This analysis breaks down the catalysts, risks, ...
Two overlooked satellite operators are quietly fueling the space economy in 2026, delivering real revenue and defense...
A veteran financial writer dives into a framework that aims to outpace the S&P over generations. Learn how Davis Fund...
Investors are sizing up whether prediction: micron technology stock could jump after the June 24 earnings reveal. Thi...
Retirees face a new financial frontier: funding long-term care for an adult child with chronic health needs. This pie...
MapleStory Universe opens space and launches a global game jam with a $60,000 NXPC prize, marking a major milestone f...
If you’re worried about crash artificial headlines in AI stocks, a simple, cost-efficient solution can help: diversif...
Strategy shareholders approved a plan to start semi-monthly dividends on STRC preferred stock, aiming to steady price...
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Chewy’s stock action in May left investors asking what happened and what comes next. This article breaks down the cat...
A sudden price collapse in a toll-tech stock creates a rare chance for patient investors. This guide explains how to ...
When billionaire Dalio just warned about AI hype, it sparked a wider discussion on valuations and risk. This guide ex...